Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes

This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30–35 and >35 kg/m2) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice da...

Full description

Bibliographic Details
Main Authors: Wolffenbuttel, B. H. R., Van Gaal, L., Durán‐Garcia, S., Han, J.
Format: Online
Language:English
Published: Blackwell Publishing Ltd 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111732/
id pubmed-5111732
recordtype oai_dc
spelling pubmed-51117322016-11-16 Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes Wolffenbuttel, B. H. R. Van Gaal, L. Durán‐Garcia, S. Han, J. Research Letters This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30–35 and >35 kg/m2) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30‐week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline BMI with changes in efficacy variables was observed. Glycated haemoglobin (HbA1c) reductions were significant (p < 0.0001) and similar across BMI range groups in the lispro‐comparator study and greater for exenatide versus placebo in the placebo‐controlled study. Significant weight loss occurred with exenatide across BMI range groups (p < 0.0001), while weight increased with both comparators. Achievement of HbA1c <7.0% (<53 mmol/mol) without weight gain was greater for exenatide versus comparators. Systolic blood pressure decreased across BMI range groups with exenatide in the lispro‐comparator study (p < 0.0001); changes in lipids were not clinically meaningful. Minor hypoglycaemia was less frequent for exenatide versus insulin lispro. These findings suggest that BMI alone should not limit clinical decision‐making or patient access to medication. Blackwell Publishing Ltd 2016-05-18 2016-08 /pmc/articles/PMC5111732/ /pubmed/27027802 http://dx.doi.org/10.1111/dom.12669 Text en © 2016 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Wolffenbuttel, B. H. R.
Van Gaal, L.
Durán‐Garcia, S.
Han, J.
spellingShingle Wolffenbuttel, B. H. R.
Van Gaal, L.
Durán‐Garcia, S.
Han, J.
Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
author_facet Wolffenbuttel, B. H. R.
Van Gaal, L.
Durán‐Garcia, S.
Han, J.
author_sort Wolffenbuttel, B. H. R.
title Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
title_short Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
title_full Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
title_fullStr Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
title_full_unstemmed Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
title_sort relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
description This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30–35 and >35 kg/m2) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30‐week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline BMI with changes in efficacy variables was observed. Glycated haemoglobin (HbA1c) reductions were significant (p < 0.0001) and similar across BMI range groups in the lispro‐comparator study and greater for exenatide versus placebo in the placebo‐controlled study. Significant weight loss occurred with exenatide across BMI range groups (p < 0.0001), while weight increased with both comparators. Achievement of HbA1c <7.0% (<53 mmol/mol) without weight gain was greater for exenatide versus comparators. Systolic blood pressure decreased across BMI range groups with exenatide in the lispro‐comparator study (p < 0.0001); changes in lipids were not clinically meaningful. Minor hypoglycaemia was less frequent for exenatide versus insulin lispro. These findings suggest that BMI alone should not limit clinical decision‐making or patient access to medication.
publisher Blackwell Publishing Ltd
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111732/
_version_ 1613729318191497216

Similar Items